Gottlieb On Being Senate-Confirmed US FDA Commissioner: It's Certainly An Advantage
Executive Summary
US FDA would have more influence in inter-agency turf battles, can build stronger relationships on Capitol Hill with a confirmed commissioner, Scott Gottlieb says.
You may also be interested in...
Gottlieb's Short Tenure Will Be Felt Long After He Leaves US FDA
Commissioner Scott Gottlieb will leave FDA less than two years after his confirmation, but will exit with a substantial list of accomplishments for industry and patients.
US FDA Creates Expedited Review For Military-Related Products
All 'top priority' battlefield products will get FDA review by June 30; longer term plan includes draft guidance on development of products designed for use in austere conditions.
Battlefield Emergency Use Bill Faces Pushback From US FDA, Authorizing Committees
Top Republicans on FDA authorizing committees worry that undermining agency's sole authority to approve drugs and devices would bring more harm than good.